These positions are aimed at candidates seeking research experience to strengthen their higher degree applications. The positions will be directly supervised and mentored by post-doctoral researchers whose responsibility will include support for these applications. Your CV will be further enhanced by contributing to the completion of papers on modified mRNA therapeutics, cancer and infectious disease vaccines. The group has made significant contributions in the areas of mRNA therapeutics1, vaccine responses2, and measurements of immune responses3,4 and the ongoing projects will extend these discoveries.

Candidates will hold, or be close to completing, an undergraduate or Masters' degree in an appropriate field (e.g. Immunology, biomedical science, biochemistry, Molecular biology) and/or have relevant experience at an equivalent level, together with some hands-on experience in animal handling, flow-cytometry RNA/ protein analytical techniques, microscopy and tissue culture. You will be able to work both independently and as part of a team, have excellent communication, organisational and problem-solving skills and ideally have experience of working on an independent research project. Enthusiasm for working in a diverse inter-disciplinary team is desirable.

References:
1. Mulroney, T. E. et al. N(1)-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature 625, 189-194, doi:10.1038/s41586-023-06800-3 (2024).
2. Van der Klaauw, A. A. et al. Accelerated waning of the humoral response to COVID-19 vaccines in obesity. Nat Med, doi:10.1038/s41591-023-02343-2 (2023).
3. Fischer, K. et al. Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells. Nat Biotechnol, doi:10.1038/s41587-024-02346-5 (2024).
4. Takahashi, M. et al. Intratumoral antigen signaling traps CD8(+) T cells to confine exhaustion to the tumor site. Sci Immunol 9, eade2094, doi:10.1126/sciimmunol.ade2094 (2024).

Fixed-term: The funds for this post are available for 12 months in the first instance.